Press Releases

Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability. We are making better chemistry biologically.

Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand

EMERYVILLE, Calif. and LEÓN, Spain, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of pure, sustainable, fermentation-derived ingredients for Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has executed an expanded agreement for its existing production contract with ADL Bionatur Solutions (MAB:ADL), through its fermentation division ADL Biopharma. ADL Bionatur, a European leader in research and development of health products, services and industrial fermentation production, provides cost effective, contract manufacturing capabilities. This marks the second expansion of an agreement the parties executed in 2018.

This expanded agreement supports confidence in ADL Bionatur Solutions by Amyris, a science and technology company that continues to establish its reputation for its fermentation process and clean, best-in-class performing ingredients.   

“We are very pleased with the production quality and cost we’ve achieved and our ability to access sugarcane-based feedstock for our fermentation capacity at ADL in Spain. This asset combined with our expanded access to the DSM-owned Brotas facility enables us the flexibility to meet growing demand from our customers. With a significant volume of ingredients produced at this site during the second half we can confirm no expected negative change to our gross margin target as a result of this expansion,” said Eduardo Alvarez, Amyris Chief Operating Officer.

The execution of a second expansion to the scope of the agreement in such a short time means, for Pilar de la Huerta, CEO of ADL Bionatur Solutions, "A clear recognition of the experience, capacity and technical knowledge of the company ADL Biopharma and the trust that Amyris has in us.  Additionally, this exponential growth of our turnover associated with new contracts, demonstrates the behavior of the demand for these types of products in the market."  Furthermore, she said, "It reinforces our sales targets for 2018, which we maintain at around double of our turnover in 2017. Currently, the company has already committed more than 85% of its fermentation capacity for the next two years for our customers."

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

About ADL Bionatur Solutions

ADL Bionatur Solutions, controlled by the investment fund Black Toro Capital (BTC) with 73% of the capital, is the company resulting from the integration of ADL Biopharma and Bionaturis. This integration involves combining in a single entity the specialization in R&D in health products and services, with industrial production by fermentation and manufacturing capacity. ADL Bionatur Solutions is listed on the MAB (Ticker ADL) since May 2018. Its main brands are ADL Biopharma, Bionaturis, Biobide and Zip Solutions. The company provides qualified employment to more than 290 people and its markets are mainly located in Europe and the United States. www.adlbionatur.com 

Amyris Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected product demand and Amyris’s ability to meet such demand, and anticipated gross margin. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.

Contacts:

Amyris
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc. 
+1 (510) 740-7481
investor@amyris.com

ADL Bionatur Solutions
Blanca San Roman 
Director, Investor Relations and Corporate Communications
ir@adlbionatur.com

MC Services
Raimund Gabriel
Tel.: +49 89 21022880
ADLbionatursolutions@mc-services.eu 

Contact Us

Beth Bannerman
Senior Vice President, Corporate Communications & Engagement
Amyris, Inc. 
pr@amyris.com